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Abstract: Pyrazinamide (PZA) has been in use for almost 50 years as a first-line drug for 
short-course chemotherapy against Mycobacterium tuberculosis. In this study, PCR 
mediated automated DNA sequencing is used to check the prevalence of PZA resistance 
among treatment failure cases of pulmonary tuberculosis. Out of 50 clinical isolates 
examined, 39 had mutations in the pncA gene that encodes Pyrazinamidase, an enzyme 
required to activate PZA. Of these, 31 (79.5%) were localized to three regions of pncA. We 
found two isolates with hitherto unreported mutation at amino acid 26 (Ala→Gly) of pncA.  
Keywords: PZA resistance; mycobacterium tuberculosis; pulmonary tuberculosis; 
South-India; pncA mutation 
 
1. Introduction 
Pyrazinamide (PZA); a nicotinamide analog, has been in use for almost 50 years as a first-line drug 
for short-course chemotherapy against Mycobacterium tuberculosis. PZA is bactericidal to 
semidormant mycobacteria and reduces the total tuberculosis treatment time when used in combination 
with isoniazid and rifampin. This has made PZA the third most important drug in the list of modern 
therapy for tuberculosis [1]. PZA plays a unique role in achieving this shortened therapy, because PZA 
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appears to kill at least 95% of the semi-dormant bacterial population persisting in a low-pH 
environment, since its activity is present only in the acidic environment found in active inflammation [2].  
Pyrazinamide is a prodrug that must be activated by a bacterial pyrazinamidase (PZase) enzyme to 
the active form pyrazinoic acid (POA), which is toxic to M. tuberculosis. Although a specific target for 
POA remains unknown, it has been suggested that POA accumulation results in a pH reduction which, 
in turn, leads to a non-specific inhibitory effect on cellular metabolism [3,4]. Recently, it has been 
shown that POA can disrupt M. tuberculosis membrane potential, affecting the transport function at an 
acidic pH. Pyrazinamidase (PZase) is a non-essential enzyme encoded by the pncA gene. Mutations in 
the pncA gene causing pyrazinamide resistance have been well characterized [5] and are located along 
the entire pncA gene open reading frame as well as in its putative regulatory region
 [6]. These 
mutations lead to loss of PZase activity, and hence the mutant will not be able to activate pyrazinamide 
to form POA. 
Conventional pyrazinamide susceptibility testing by agar proportion or by Lowenstein–Jensen 
proportion method is labor intensive and may exhibit high discordance rates among different 
laboratories as the media pH and other parameters are known to influence the outcome of the 
susceptibility testing [7]. Automated systems, such as the BACTEC 460 TB system, BACTEC MGIT 
960 are commercially available, but are expensive and impractical to use in developing countries 
where the prevalence of tuberculosis is high. Many earlier studies have shown that inactivation of the 
pncA gene by mutations is the major mechanism for resistance to PZA [8]. This study was designed to 
determine the frequency and the distribution of the pncA mutations among failed treatment cases of 
pulmonary tuberculosis in South India. In vitro susceptibility to PZA was correlated with PZase 
activity and the pncA nucleotide sequence.  
2. Results and Discussion 
A clear PCR product band of 123 base pairs (bp) was observed on a 2% agarose gel confirming the 
M. tuberculosis (Figure 1).The observation of a clear band at the 222 bp region on 2% agarose gel 
confirmed the amplification of the pncA gene of M. tuberculosis (Figure 2).The PCR products were 
analyzed on a Bioanalyzer (Agilent 2100) to check the purity and specificity of the products. 
Electropherogram analysis of the PCR-amplified pncA gene confirmed the molecular size (222 bp) of 
the products (Figure 3). 
Figure 1. PCR Amplification for Species Identification. Lane 1: 100 bp DNA ladder,   
Lane 3:123 bp PCR amplified product. 
1      2     3 
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Figure 2. PCR Amplification of pncA. Lane 1: 100 bp DNA ladder, Lane 3: 222 bp PCR 
amplified pncA gene product.  
1     2     3 
 
Figure 3. Electropherogram Analysis of PCR Amplified Products. Peak 1: Lower Marker 
(15 bp), Peak 2: PCR amplified product of pncA gene (222 bp) and Peak 3: Upper marker 
(1500 bp). 
 
 
We analyzed 50 clinical isolates of M. tuberculosis from treatment failure cases to find mutations in 
the pncA gene. In vitro susceptibility testing showed that 39 of these isolates were resistant to PZA 
with minimal inhibitory concentrations (MIC) of 300 µg/mL, and 11 out of 50 were PZase positive and 
susceptible to PZA with a minimal concentration of 100 µg/mL (Table 1). The results of the sequence 
analysis of pncA  from 39 PZA-resistant isolates are presented in Table 2. We found nucleotide 
substitutions and insertions leading to change in the amino acids. The nature of the pncA mutations 
includes substitutions of amino acids (33 of 39 totals PZA-resistant isolates with pncA mutations), 
insertions causing nonsense peptides (6 of 39 isolates). The distribution of pncA mutations is dispersed 
along the gene. The reason for treatment failure in the 11 PZA sensitive cases could be due to some 
other mechanisms. The susceptible clinical M. tuberculosis isolates were found to have identical   
wild-type sequence, while 75–95% of PZA resistant isolates had a point mutation (mis-sense/nonsense 
or insertion/deletion) and these were spread over the entire length of the pncA  gene [9–11] It is 
generally considered that mutations leading to PZA resistance are scattered along the pncA   
gene [12,13]. However, some authors have mentioned a certain degree of conservation of pncA Int. J. Mol. Sci. 2010, 11                 
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mutations at amino acid residues 3 17, 61–76 and 132–142 in the PZase protein [14–16]. We found 
that 35.9% of the mutations are located in regions that are different from those reported previously 
[17]. Mutations were observed in the regions between residues 132 and 142, and in 33.3% between 
residues 69 and 72, in 15.4% and 15.4% of the mutations were found between residues 5 and 12. 
Among the PZA resistant isolates, 39 (41%) exhibited 16 different changes in pncA nucleotide 
sequence (Table 1). The mutations in pncA included thirteen nucleotide substitutions causing amino 
acid change in 33 isolates, mutations caused by three insertions in six isolates. In this study we have 
not observed the relationship between pyrazinamide MIC values and mutation frequency or position. 
However, it was observed that every isolate that presented a pncA alteration lacked PZase activity 
(Table 2). Prior studies have shown that common mutations in the pncA are located in three regions, 
3–17, 61–85 and 132–142 [2]. In this study we find that one third of the mutations are distributed in 
the 132–142 region and 30.7% of mutations from 12 isolates are located in the 61–85 region. The 
region 3–17 accounts for mutations in 6 (15%) of the resistant isolates. Overall, these three regions 
alone contribute to drug resistant mutations in 79.5% of the isolates. These three regions are important 
in the formation of the active site of the enzyme [2]. Three isolates showed mutations at K96 and two 
isolates were mutated at H51. K96 and H51 are also important at the active site and earlier studies have 
reported mutations at these two sites [2]. We found one isolate mutated at A171. This mutation has 
been reported in a prior study from Portugal [6]. In our study, we found two isolates (5.1%) showing a 
unique mutation at A26. The G→C nucleotide changes of both strains led to substitution of a nonpolar 
amino acid Alanine to another nonpolar amino acid Glycine (Ala→Gly). This mutation has not been 
reported earlier and the significance of this mutation on PZase activity is not clear. Eleven clinical 
isolates carried the wild-type pncA sequence and retained PZase activity. This finding supports the 
hypothesis that other mechanisms may be involved in PZA resistance—possibly alteration in 
Pyrazinamide uptake,
 increased POA active efflux
 [18] or mutations leading to the modification or 
amplification of an unknown POA target
 [19].The resistant pattern of clinical isolates due to mutations 
detected by PCR mediated DNA sequencing were matched with that of in vitro sensitivity tests done 
on L.J. slants (Table.1). This suggests that mutations in the pncA  gene are indicative of PZA 
resistance, and the importance of PCR mediated pncA gene sequencing in detecting PZA resistance is 
established.  
Table 1. Comparison of in vitro testing (on isolates) with PCR mediated direct sequencing. 
PCR Mediated Direct 
sequencing 
In vitro sensitivity tests on L.J. slants (µg/mL) 
Susceptibility Resistance 
PZase activity 
(MIC = 100)  MIC = 300  MIC > 300 
Resistant 39 (78%)  00  26(52%)  13(26%)  Negative 39 (78%) 
Sensitive 11 (22%)  11(22%)  --  --  Positive 11 (22%) 
Total 50 (100%)  11(22%)  39(78%)  Total 50 (100%) 
The present study is one of the first studies on  pncA gene mutations in clinical isolates of   
M. tuberculosis in South India. We found that PCR mediated gene sequencing is an effective method 
for reliable identification of PZA resistance. This study suggests that the enzymatic activity is very 
sensitive to sequence alterations in any protein region of the pncA gene and most of the PZA-resistant Int. J. Mol. Sci. 2010, 11                 
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M. tuberculosis strains have mutations in the pncA gene, which has implications for developing a rapid 
test for detecting PZA-resistant M. tuberculosis strains. The diversity of methods currently used in 
clinical laboratories for the detection of PZA resistance in M. tuberculosis isolates causes inconsistent 
results of PZA susceptibility testing [20]. Inconsistent results of PZA susceptibility testing have been 
reported by a number of laboratories by various methods, including the qualitative BACTEC test [21]. 
On the basis of our analyses of the PZA-resistant clinical isolates, there is a very good correlation 
between the loss of PZase activity and pncA mutations and PZA resistance. These findings are the 
basis for designing PCR mediated DNA sequencing tests to rapidly detect pncA  mutations as a 
correlation of PZA resistance. Analysis of the pncA sequence has found that five PZA-resistant strains 
determined by the conventional method are in fact susceptible, indicating that the sequence-based test, 
e.g., direct sequencing by PCR, may be more accurate or reliable. We have demonstrated in this study 
that pncA  mutations in PZA-resistant strains can be readily detected by the PCR mediated DNA 
sequencing technique. Thus, detection of pncA mutations by direct sequencing is not only fast, but also 
will avoid the problems of current PZA susceptibility testing. The diversity of mutations makes it 
unlikely that a suitable molecular method could be devised for rapidly determining the resistance to 
pyrazinamide in clinical M. tuberculosis isolates. This could be useful for directing the treatment of 
tuberculosis, reducing treatment costs, and potentially limiting the spread of drug-resistant   
M. tuberculosis isolates. The results presented in this study contribute to the knowledge of the 
molecular mechanisms and epidemiology of pyrazinamide resistance in South India as well as to 
expanding the known profiles of pncA mutations worldwide. The PCR mediated direct DNA 
sequencing method seems to have great potential and needs further evaluation for rapid determination 
of M. tuberculosis susceptibility to pyrazinamide. 
Table 2. pncA nucleotide and amino acid changes in PZase–negative M. tuberculosis 
clinical isolates. 
Mutation 
Site 
Nucleotide 
Changes 
Amino Acid Changes  No. of Isolates  Percentage (%) 
137 A→C His→Pro 2 5.1 
138 G→A Cys→Tyr 2 5.1 
139 G→C Val→Leu 2 5.1 
5.1  142 C→T Thr→Met 2 
5 AT  insertion  Ile→Ser 2 5.1 
12 A→C Asp→Ala 4 10.3 
26 G→C Ala→Gly 2 5.1 
51 C→G His→Gln 2 5.1 
69 C→G Pro→Arg 3 7.7 
72 T→C Cys→Arg 3  7.7 
85 T→C Leu→Pro 6 15.4 
96 A→C Lys  →Asn 37.7   
132 TC  insertion  Gly→Ser 3 7.7 
141 C→A Gln→Pro 1 2.6 
142 AG  insertion  Thr→Lys 1 2.6 
171 
Total 
G→C 
 
Ala→Pro 
 
1 
39 
2.6 
100 Int. J. Mol. Sci. 2010, 11                 
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3. Experimental Section 
3.1. Bacterial Samples 
A total of 50 clinical strains of Mycobacterium tuberculosis were isolated from sputum samples of 
treatment failure cases hospitalized at State TB Training and Demonstration Centre (Intermediate 
Reference Laboratory) Government Hospital for Chest Diseases, Puducherry, South India, during the 
period from January 2006 to November 2008. Among the 50 sputum samples collected, 32 samples 
were from patients of Puducherry state and 18 samples were from the other neighboring border states 
of Puducherry in India. All specimens were processed immediately and aliquots of the decontaminated 
specimens were kept at −20 °C 
3.2. Sputum Processing for AFB Culture 
To each volume of sputum, 2 volumes of 4% NaOH were added. The bottles were shaken by hand 
for 1 minute. Then the bottles were placed in a rack on the shaking machine and were left to shake 
gently for 20 minutes. The specimens were removed from the shaker. The sputum bottles were 
centrifuged for 15 minutes at 4000 rpm. After the bottles were removed from the centrifuge, the 
supernatant was carefully poured off into the disinfectant bath. The bottles were filled with 20 mL of 
sterile distilled water, shaken by hand to mix the deposit and were centrifuged for 15 minutes at  
4000 rpm. The supernatant was poured off and finally the sediment was inoculated with a 5 mm 
diameter loop onto the pre-sterilized and numbered Lowenstein-Jensen’s slopes. The inoculated media 
was placed in the 37 °C incubator
 [22,23]. 
3.3. Drug Susceptibility Test-Proportion Method (Stand and Economic Variant) 
With a loop, a representative sample of approximately 4–5 mg is taken from the primary culture and 
placed in a McCartney bottle containing 1 mL sterile distilled water and 3 mm diameter of 6 glass 
beads. The bottle was vortexed for 20–30 seconds and the opacity of the bacterial suspension was then 
adjusted by the addition of distilled water to obtain a concentration of 1mg /mL of tubercle bacilli by 
matching with McFarland standard No.1. After preparing the standard neat suspension, the   
dilution 10
-2 dilution 10
-4 were produced by discharging two loopfuls (24 SWG-3 mm Nichrome wire) 
of the bacterial suspension. The contents were mixed by shaking. Two slopes of medium without drug, 
and two slopes of acidified L.J media are used as controls for the test, and one slope of medium with 
Pyrazinamide drug (100 µg/mL) are inoculated with a loopful of each dilution. The slopes were 
incubated at 37 °C and the proportion tests were read at 28 days and again at 42 days
 [24].  
3.4. PZase Assay 
The PZase assay was performed by the method described in the Clinical Microbiology Procedure 
Handbook [25]. Briefly, 6.5 g of Dubos broth base, 0.1 g of PZA, 2.0 g of sodium pyruvate and 15.0 g 
of agar were dissolved in 1 L of distilled water and heated to dissolve the components. The solution 
was dispensed in 5-mL amounts into screw-cap tubes and stored at 2 to 8 °C until use after 
solidification of the agar with the tubes in an upright position. A heavy loopful of growth from an Int. J. Mol. Sci. 2010, 11                 
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actively growing subculture was inoculated. After incubation at 37 °C for 4 or 7 days, 1 mL of freshly 
prepared 1% ferrous ammonium sulfate was added to each tube. A pink band in the agar indicated a 
positive test. 
3.5. Mycobacterium DNA Extraction 
One loopful of culture was homogenized in 100 μL of sterile distilled water. The entire 
homogenized samples were treated with 50 μL of lysozyme (10 mg/mL) at 37 °C for overnight 
incubation. 70 μL of 14% SDS and 6 μL of Proteinase K (10 mg/mL) was added and incubated at  
65 °C for 15 minutes. 10 μL of 5 M NaCl and 80 μL of CTAB/NaCl were added and was incubated at 
65 °C for 10 minutes. 800 μL of Phenol: Chloroform: Isoamylalcohol (25:24:1) mixture was added and 
centrifuged at 10,000 rpm for 10 minutes. The supernatant was transferred to a fresh tube and 600 μL 
of Isopropanol was added to precipitate the DNA and incubated overnight at −20 °C.Centrifuged at 
12,000 rpm in 4 °C for 10 minutes. The pellet was washed with 70% ethanol to remove any remaining 
solutes. The pellet was air-dried and was dissolved in 20 μL of 1× TE buffer [26]. 
3.6. PCR Amplification for Species Identification 
The isolated template DNA was amplified using IS6110 primer in an authorized thermal cycler 
(Eppendorf Gradient Cycler). This confirmed that the template DNA of the clinical isolates was 
Mycobacterium tuberculosis. The PCR reaction was set up as follows using the primer for 
Mycobacterium IS6110 amplification F 5’GTGAGGGCATCGAGGTGG 3’ (10 pmol/μL) R 
5’CGTAGGCGTCG GTCACAAA 3’ (10 pmol/μL) [27]. The PCR cycling parameters were 94 °C for 
5 minutes; followed by 40 cycles of 94 °C for 1 minute, 57 °C for 1 minute and 72 °C for 1 minute; 
and a final extension of 72 °C for 10 minutes. The PCR was then kept at hold at 4 °C for 15 minutes. 
The amplified PCR product was withdrawn from thermal cycler and run on a 2% Agarose gel in TAE 
buffer. The Ethidium bromide stained gels were observed in a UV Transilluminator and photographed 
using a Geldoc. 
3.7. PCR Amplification of pncA 
The isolated template DNA was amplified using pncA  primers (P1 5’GTCGGTCATGTTCG 
CGATCG, and P2 5’TCGGCCAGGTAGTCGCTGAT) [28] in an authorized thermal cycler 
(Eppendorf Gradient Cycler). The PCR cycling parameters were 94 °C for 5 minutes; followed by 40 
cycles of 94 °C for 1 minute, 57 °C for 1 minute and 72 °C for 1 minute; and a final extension of 74 °C 
for 10 minutes. The PCR was then kept at hold at 4 °C for15 minutes. The amplified PCR product was 
withdrawn from thermal cycler and run on a 2% Agarose gel in TAE buffer. The Ethidium bromide 
stained gels were observed in a UV Trans illuminator and photographed using a Geldoc. 
3.8. Agarose Gel Electrophoresis 
The gel running tray was placed in a clean gel casting tray to form the gel uniformly and the comb 
was fixed at one end. 400 mg of agarose (2%) powder was added to 20 mL of 0.75 × TAE and was 
boiled to dissolve the agarose completely. Less than 1 μL of Ethidium bromide (0.5 mg/mL) was Int. J. Mol. Sci. 2010, 11                 
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added into the hand bearable heat 250 mL conical flask containing melted agarose gel and was poured 
into the gel running tray. 1 μL of gel loading dye was transferred into a 5 × 5 cm size Para film. To it,  
5 μL of polymerized DNA was added and mixed thoroughly. The whole volume aliquot of amplified 
sample with gel loading dye was loaded into a well of 2% agarose gel in 0.75 × TAE buffer and was 
subjected to electrophoresis for 30 minutes at 100 volts. The gel was observed under UV 
Transilluminator for specific DNA bands and was photographed. The DNA bands were identified 
according to size by comparing with the molecular weight marker (100 bp DNA ladder) loaded in a 
separate lane. 
3.9. Electropherogram Analysis of PCR Amplified Products 
DNA dye concentration and DNA gel matrix were allowed to equilibrate at room temperature. 
25 μL of dye concentration was added to DNA gel matrix, vortexed and transferred to spin filter and 
centrifuged at 2240 g for 15 minutes. The gel dye was allowed to settle at room temperature for  
30 minutes. A new DNA chip was placed on the chip priming station. 9 μL of gel dye mix was pipetted 
into the well marked as G and the chip priming station was closed. The plunger was pressed down until 
it is held by the chip for 60 seconds. After 5 seconds the plunger was pulled back slowly to 1 mL 
position. The chip priming station was opened and 9 μL of gel dye was pipetted into the well marked G 
and 1 μL of ladder was added to the well labeled ladder. 5 μL of marker was pipetted into all 12 
sample wells and in ladder well. 1 μL of sample was added into the well. The chip was placed in the 
Laser Induced Fluorescent instrument (Bioanalyzer-Agilent 2100) and the results were 
interpreted [29]. 
3.10. DNA Sequencing 
The amplified PCR product pncA gene from clinical isolate strains were run on 2% Agarose gel and 
the PCR product purified using PCR purification kit (Invitrogen). The purified PCR product was 
directly sequenced in an automated DNA Sequencer at Bioserve in Bangalore. The nucleotide 
sequence obtained was analyzed using BLASTn Bioinformatics tool available at National Center for 
Biotechnology Information [30] to know the specificity of PCR amplification and to identify the 
nucleotide variation. The sequence was further subjected for BLASTx to identify the amino acid 
changes in comparison with the wild type Mycobacteruim tuberculosis (H37Rv). 
4. Conclusions 
The worldwide emergence and spread of multi drug-resistant (MDR) strains of Mycobacterium 
tuberculosis has adverse effects on tuberculosis (TB) control programs. The goal of this paper is to 
describe the advances made in the understanding of the molecular basis of M. tuberculosis resistance 
to PZA, and to discuss the potential of molecular methods in early diagnosis of PZA drug-resistant TB. 
In the present study, out of 50 clinical isolates examined, 39 had mutations in the pncA gene. Of these, 
31 (79.5%) were localized to three regions of pncA. We found two isolates with hitherto unreported 
mutation at position 26 (Ala→Gly) of pncA. We observed that the 39 clinical isolates had a pncA gene 
alteration and lacked PZase activity. The reason for treatment failure in the 11 PZA sensitive cases Int. J. Mol. Sci. 2010, 11                 
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could be due to some other mechanisms. This suggests that the enzymatic activity is very sensitive to 
sequence alterations in any protein region. Our finding that most PZA-resistant M. tuberculosis strains 
have mutations in the pncA  gene has implications for developing a rapid test for detecting   
PZA-resistant M. tuberculosis strains.  
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